We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+27.7%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.4B
AUM Growth
+$1.73B
Cap. Flow
-$958M
Cap. Flow %
-5.21%
Top 10 Hldgs %
90.4%
Holding
118
New
7
Increased
23
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$60.8M
2
SWTX
SpringWorks Therapeutics
SWTX
+$35.8M
3
ROIV icon
Roivant Sciences
ROIV
+$33.4M
4
KYNB
Kyntra Bio
KYNB
+$26.7M
5
BPMC
Blueprint Medicines
BPMC
+$15M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$605M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$395M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$110M
4
TVTX icon
Travere Therapeutics
TVTX
+$25.8M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTH
101
DELISTED
Genetron Holdings Limited ADS
GTH
$478K ﹤0.01%
151,769
– –
FHTX icon
102
Foghorn Therapeutics
FHTX
$278M
$279K ﹤0.01%
45,027
– –
VINC
103
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$251K ﹤0.01%
12,069
– –
SRZNW icon
104
Surrozen Inc Warrant
SRZNW
$36.6K
$83.3K ﹤0.01%
833,333
– –
BLCM
105
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$82.2K ﹤0.01%
249,123
– –
ALT icon
106
Altimmune
ALT
$568M
– –
-653,562
Closed -$10.8M
ASND icon
107
Ascendis Pharma A/S
ASND
$16.5B
– –
-4,954,855
Closed -$605M
BHVN icon
108
Biohaven
BHVN
$2.02B
– –
-476,190
Closed -$6.61M
KRON
109
DELISTED
Kronos Bio
KRON
– –
-1,198,151
Closed -$1.94M
KZR
110
DELISTED
Kezar Life Sciences
KZR
– –
-6,195
Closed -$436K
TVTX icon
111
Travere Therapeutics
TVTX
$5.17B
– –
-1,225,255
Closed -$25.8M
ZYME icon
112
Zymeworks
ZYME
$1.62B
– –
-1,708,472
Closed -$13.4M
ATYR
113
aTyr Pharma
ATYR
$47.4M
– –
-8,565
Closed -$18.8K
CBAY
114
DELISTED
Cymabay Therapeutics
CBAY
– –
-2,170,464
Closed -$13.6M
CYT
115
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-2,492,118
Closed -$4.11M
RETA
116
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-223,976
Closed -$8.51M
CINC
117
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-807,212
Closed -$9.92M
HZNP
118
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-969,727
Closed -$110M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Baker Bros. Advisors held 118 positions worth $18.4B, up 10% from $16.7B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors withdrew a net $958M in Q1 2023, closing 13 positions and reducing 7 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $605M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Blueprint Medicines worth $15M.

  • Baker Bros. Advisors's largest Q1 2023 buy was Blueprint Medicines: 333,665 shares worth $15M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2023, an estimated $60.8M increase.
  • Baker Bros. Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $395M.
  • Baker Bros. Advisors fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $605M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $18.4B portfolio in Q1 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 13 in Q1 2023.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $18.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.